替沙基仑赛治疗唐氏综合征相关复发/难治性急性淋巴细胞白血病的儿童及年轻成人患者
纳入16例唐氏综合征相关急性淋巴细胞白血病(DS-ALL)患者,来自两项2期试验(ELIANA、ENSIGN)及一项3b期管理准入方案(B2001X)。14/16例(88%)达完全缓解(CR)或血细胞计数未完全恢复的CR(CRi),其中12/14例(86%)微小残留病阴性。中位随访13.2个月,6例(43%)缓解后复发。与无唐氏综合征的ALL患者相似,替沙基仑赛产生高缓解率、副作用可控并有前景的长期结局。
要点
- 16例DS-ALL患者中14例(88%)达CR/CRi,其中12/14例(86%)MRD阴性。
- 中位随访13.2个月,6例(43%)缓解后复发(3例CD19阴性,3例未知)。
- 44%发生3/4级细胞因子释放综合征,13%发生3/4级神经系统事件,44%发生3/4级持续性血细胞减少。
核心结论
- 与无唐氏综合征的ALL患者相比,替沙基仑赛在儿童/年轻成人DS-ALL患者中产生高缓解率、副作用可控并有前景的长期结局。
研究设计与样本
- 研究纳入16例DS-ALL患者,来自两项2期试验(ELIANA [NCT02435849]、ENSIGN [NCT02228096])及一项3b期管理准入方案(B2001X [NCT03123939])。
- 患者年龄5-22岁,既往治疗线数中位2线(范围1-4),4例(25%)既往接受过干细胞移植。
主要发现
- 14/16例患者(88%)达到CR或CRi;12/14例(86%)达到CR/CRi的患者为微小残留病阴性。
- 中位随访13.2个月(范围0.5-49.3个月),6例患者(43%)在CR后复发(3例CD19阴性,3例未知),复发时间在输注后80-721天。
- 9例患者持续缓解,缓解持续时间6-48个月。
- 任何级别和3/4级不良事件分别发生于16例和14例患者;44%发生3/4级细胞因子释放综合征,13%发生3/4级神经系统事件。
- 44%患者发生3/4级持续性血细胞减少;未观察到3/4级感染。
临床怎么用
- 作者认为,DS-ALL患者有独特的医疗需求,替沙基仑赛可能帮助他们延长生存、避免干细胞移植及化疗毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Down syndrome-associated acute lymphoblastic leukemia (DS-ALL) patients suffer risk of chemotherapy-associated toxicities and poor outcomes. We evaluated tisagenlecleucel in 16 patients with DS-ALL in two phase 2 trials (ELIANA [NCT02435849], ENSIGN [NCT02228096]) and a phase 3b, managed access protocol (B2001X [NCT03123939]). Patients were 5-22 years old, had a median of two prior lines of therapy (range, 1-4), and four (25%) had prior stem cell transplants. Fourteen of 16 patients (88%) achieved complete remission (CR) or CR with incomplete blood count recovery (CRi); 12 of 14 (86%) with CR/CRi were minimal residual disease-negative. With a median follow-up of 13.2 months (range, 0.5-49.3 months), six patients (43%) relapsed after CR (three, CD19-negative; three, unknown) between 80-721 days post-infusion. Ongoing remissions in nine patients ranged from 6-48 months. Any-grade and grade 3/4 AEs occurred in 16 and 14 patients, respectively; 44% experienced grade 3/4 cytokine release syndrome and 13% experienced grade 3/4 neurological events. Grade 3/4 prolonged cytopenias occurred in 44% of patients. No grade 3/4 infections were observed. Tisagenlecleucel expansion and long-term persistence were consistent with previous reports. Comparable to ALL patients without DS, tisagenlecleucel produced high remission rates, manageable side-effects, and promising long-term outcomes in pediatric/young adult patients with DS-ALL. Children with Down syndrome have a 20 times higher risk of developing a type of blood cancer called Down syndrome-associated acute lymphoblastic leukemia (ALL). Children who develop Down syndrome-associated ALL typically receive chemotherapy to treat their cancer; however, they can experience severe toxicity or other consequences from these therapies, especially stem cell transplant, and have a poor prognosis if their disease returns after treatment. These children need an effective but less toxic treatment option. Tisagenlecleucel is a chimeric antigen receptor-T cell therapy that specially modifies the patient’s own T-cells to recognize and attack the cancer cells. Tisagenlecleucel is approved for use in children and young adults with ALL whose disease reappears after two or more treatments or whose disease doesn’t respond to treatment. Here we present data from 16 patients across three clinical studies showing that tisagenlecleucel is well-tolerated and an effective treatment option for children and young adults with Down syndrome-associated ALL, and was similar to what is observed in patients without Down syndrome. Taken together, patients with Down syndrome-associated ALL have unique medical needs, and tisagenlecleucel may help them live longer, avoid stem cell transplantation, and the toxicity from chemotherapy.
引用
- Laetsch TW, Maude SL, Balduzzi A, et al. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2022. PMID: 35422096. doi:10.1038/s41375-022-01550-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。